Isis Pharmaceuticals, Inc. (ISIS) today announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx. ISIS-FXIRx is an antisense drug in development for the prevention of clotting disorders.
Read the entire article here.